Physician profile
Vikas Gupta
NPI 1720367733
$2,892.03
in general payments reported to CMS, 2019-2025
20 companies · $645 in 2025
The $645 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $200 · 2021: $682 · 2022: $282 · 2023: $363 · 2024: $600 · 2025: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,581 · Education: $26.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,580.87 |
| Education | $26.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $816.36 | 2019-2025 | Fintepla, Nayzilam, Briviact |
| Livanova USA, INC. | $428.61 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Abbvie INC. | $267.01 | 2021-2025 | |
| Eisai INC. | $219.51 | 2022-2025 | |
| Sk Life Science, INC. | $204.17 | 2020-2024 | Xcopri |
| Neurelis, INC. | $159.17 | 2021-2023 | Valtoco |
| Sunovion Pharmaceuticals INC. | $140.21 | 2020-2021 | |
| Biogen, INC. | $135.14 | 2021-2022 | |
| Genentech USA, INC. | $103.41 | 2019-2022 | |
| Lilly USA, LLC | $97.50 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $63.77 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $54.13 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $44.49 | 2021 | |
| Acorda Therapeutics, INC | $40.44 | 2019 | |
| Amgen INC. | $28.21 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Upsher-Smith Laboratories LLC | $28.11 | 2021 | |
| Impel Pharmaceuticals INC. | $24.62 | 2022 | |
| Celgene Corporation | $22.12 | 2021 | |
| Currax Pharmaceuticals LLC | $14.22 | 2022 | |
| Travere Therapeutics, INC. | $0.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikas Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.